Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: prior authorization Clear all
Completed Phase 4 Interventional Results available

Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas

NCT00517296
View directory record Official record
Conditions
Crohn Disease, Rectal Fistula
Interventions
EUA with seton placement if necessary, adalimumab, EUS
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 21, 2026, 7:43 AM EDT
Completed No phase listed Observational

Direct Acting Antiviral-Post Authorization Safety Study

NCT03707080
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

NCT05555030
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
Device · Diagnostic Test
Lead sponsor
New Day Diagnostics
Network
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Anaheim, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated No phase listed Observational

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

NCT05876377
View directory record Official record
Conditions
SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Interventions
Pfizer-BioNTech COVID-19 mRNA vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed No phase listed Observational Results available

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

NCT03932799
View directory record Official record
Conditions
Opioid Use, Opioid-Related Disorders
Interventions
Prospective prior authorization (PA) with hard stops in Washington, Retrospective review (RR) with prescriber notification in Ohio
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5,411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Columbus, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 3 Interventional

A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

NCT05166161
View directory record Official record
Conditions
Phenylketonuria
Interventions
PTC923
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Gainesville, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications

NCT05463705
View directory record Official record
Conditions
Diabetes, SGLT-2i and GLP-1RA Therapies, Diffusion of Responsibility, Prescribing Burden
Interventions
Intervention to address diffusion of responsibility, Intervention to address diffusion of responsibility + simplification of prescribing
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 21, 2026, 7:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

NCT01306019
View directory record Official record
Conditions
X-linked Severe Combined Immunodeficiency (XSCID)
Interventions
Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector, Busulfan, Palifermin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

The Impact of Sharing Audio Recorded Clinic Visits on Self-management in Older Adults

NCT04344301
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension
Interventions
Audio recording
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
65 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Manchester, New Hampshire • Nashville, Tennessee • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 21, 2026, 7:43 AM EDT
Completed No phase listed Observational

Linkage to Care - Part II

NCT00891644
View directory record Official record
Conditions
HIV, Care-seeking, HIV Infections
Interventions
Case Management, Snowball sampling, Referral Lists
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
14 Years to 24 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated Phase 3 Interventional Results available

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

NCT03495921
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Building an Evidence Base for Weight Loss Strategies Among Those With Chronic SCI-The GLB-SCI+

NCT03874988
View directory record Official record
Conditions
Spinal Cord Injuries, Obesity, Weight Loss, Diet Modification
Interventions
Portion-Controlled Meals, Enhanced Self-Monitoring, GLB-SCI+
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 21, 2026, 7:43 AM EDT
No Longer Available No phase listed Expanded access

Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults

NCT03945903
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 21, 2026, 7:43 AM EDT
Completed No phase listed Observational

FQ Restriction for the Prevention of CDI

NCT03848689
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
Interventions
fluoroquinolone preprescription authorization, Control
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
5,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Moreno Valley, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

NCT00621478
View directory record Official record
Conditions
Status Epilepticus
Interventions
lorazepam or diazepam
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 18 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Davis, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 21, 2026, 7:43 AM EDT
Available No phase listed Expanded access

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

NCT07262970
View directory record Official record
Conditions
Tumor-associated Hyperinsulinism (Tumor HI)
Interventions
Ersodetug (9 mg/kg) + SOC
Drug
Lead sponsor
Rezolute
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Enrolling by invitation Not applicable Interventional

AI-Supported Care Engagement for Next-step Delivery - Medicare Advantage

NCT07804095
View directory record Official record
Conditions
Population Health Management, Patient Navigation
Interventions
AI-Supported Rising-Risk Care Navigation
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
9,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Recruiting Not applicable Interventional

Weight Bias Reducation Intervention With Nursing Students Using Simulation: The BRAVE Study

NCT07334470
View directory record Official record
Conditions
Weight Bias
Interventions
BRAVE, SOL: Standard Obesity Lecture
Behavioral
Lead sponsor
Villanova University
Other
Eligibility
18 Years to 35 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Villanova, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation

NCT05584176
View directory record Official record
Conditions
SARS-CoV2 Infection, COVID-19
Interventions
iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
Device
Lead sponsor
MP Biomedicals, LLC
Industry
Eligibility
2 Years and older
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
DeLand, Florida • Gainesville, Florida • St. Petersburg, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 4 Interventional Results available

Nebulized Hypertonic Saline for Inpatient Use in COPD

NCT02266875
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
hypertonic saline, standard saline
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 21, 2026, 7:43 AM EDT
Active, not recruiting No phase listed Observational

3D Body Surface Modeling for Scoliosis Monitoring

NCT05697939
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
NSite 3D Scanning
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management

NCT04575155
View directory record Official record
Conditions
Polypharmacy
Interventions
TEAM Strategy
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 21, 2026, 7:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effectiveness of the Consent Process

NCT00630136
View directory record Official record
Conditions
Parental Consent
Interventions
interview
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

NCT04762680
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
3,159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 21, 2026, 7:43 AM EDT